Predictive biomarkers for tumor immune checkpoint blockade

References

• SiegelRLMillerKDJemalACancer Statistics, 2017CA Cancer J Clin201767173028055103
   PubMed Web of Science ®Google Scholar
• HowladerNNooneAMKrapchoMSEER Cancer Statistics Review, 1975–2013Bethesda, MDNational Cancer Institute2016 Available from: http://seer.cancer.gov/csr/1975_2013/
   Google Scholar
• JaysonGCKerbelREllisLMHarrisALAntiangiogenic therapy in oncology: current status and future directionsLancet20163881004351852926853587
   PubMed Web of Science ®Google Scholar
• MahoneyKMRennertPDFreemanGJCombination cancer immunotherapy and new immunomodulatory targetsNat Rev Drug Discov201514856158426228759
   PubMed Web of Science ®Google Scholar
• AssiHIKamphorstAOMoukalledNMRamalingamSSImmune checkpoint inhibitors in advanced non-small cell lung cancerCancer2018124224826129211297
   PubMed Web of Science ®Google Scholar
• BoussiotisVAMolecular and Biochemical Aspects of the PD-1 Checkpoint PathwayN Engl J Med2016375181767177827806234
   PubMed Web of Science ®Google Scholar
• DongHZhuGTamadaKChenLB7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretionNat Med19995121365136910581077
   PubMed Web of Science ®Google Scholar
• LatchmanYWoodCRChernovaTPD-L2 is a second ligand for PD-1 and inhibits T cell activationNat Immunol20012326126811224527
   PubMed Web of Science ®Google Scholar
• KythreotouASiddiqueAMauriFABowerMPinatoDJPD-L1J Clin Pathol201871318919429097600
   PubMed Web of Science ®Google Scholar
• O’DaySJHamidOUrbaWJTargeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignanciesCancer2007110122614262718000991
   PubMed Web of Science ®Google Scholar
• GaronEBRizviNAHuiRKEYNOTE-001 InvestigatorsPembrolizumab for the treatment of non-small-cell lung cancerN Engl J Med2015372212018202825891174
   PubMed Web of Science ®Google Scholar
• JacquelotNRobertiMPEnotDPPredictors of responses to immune checkpoint blockade in advanced melanomaNat Commun20178159228928380
   PubMedGoogle Scholar
• BrahmerJReckampKLBaasPNivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung CancerN Engl J Med2015373212313526028407
   PubMed Web of Science ®Google Scholar
• RittmeyerABarlesiFWaterkampDOAK Study GroupAtezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialLancet20173891006625526527979383
   PubMed Web of Science ®Google Scholar
• HellmannMDCallahanMKAwadMMTumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung CancerCancer Cell2018335853861.e429731394
   PubMed Web of Science ®Google Scholar
• HellmannMDCiuleanuTEPluzanskiANivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational BurdenN Engl J Med2018378222093210429658845
   PubMed Web of Science ®Google Scholar
• CarboneDPReckMPaz-AresLCheckMate 026 InvestigatorsFirst-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung CancerN Engl J Med2017376252415242628636851
   PubMed Web of Science ®Google Scholar
• SchattonTScolyerRAThompsonJFMihmMCJrTumor-infiltrating lymphocytes and their significance in melanoma prognosisMethods Mol Biol2014110228732424258985
   PubMedGoogle Scholar
• WeissSAHanSWLuiKImmunologic heterogeneity of tumor-infiltrating lymphocyte composition in primary melanomaHum Pathol20165711612527473267
   PubMed Web of Science ®Google Scholar
• LeeNZakkaLRMihmMCSchattonTTumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapyPathology201648217718727020390
   PubMed Web of Science ®Google Scholar
• KeirMEButteMJFreemanGJSharpeAHPD-1 and its ligands in tolerance and immunityAnnu Rev Immunol20082667770418173375
   PubMed Web of Science ®Google Scholar
• RitprajakPAzumaMIntrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinomaOral Oncol201551322122825500094
   PubMed Web of Science ®Google Scholar
• AzumaKOtaKKawaharaAAssociation of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancerAnn Oncol201425101935194025009014
   PubMed Web of Science ®Google Scholar
• MarzecMZhangQGoradiaAOncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)Proc Natl Acad Sci U S A200810552208522085719088198
   PubMed Web of Science ®Google Scholar
• MadoreJVilainREMenziesAMPD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trialsPigment Cell Melanoma Res201528324525325477049
   PubMed Web of Science ®Google Scholar
• CalleaMAlbigesLGuptaMDifferential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell CarcinomaCancer Immunol Res20153101158116426014095
   PubMed Web of Science ®Google Scholar
• BorghaeiHPaz-AresLHornLNivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung CancerN Engl J Med2015373171627163926412456
   PubMed Web of Science ®Google Scholar
• McLaughlinJHanGSchalperKAQuantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung CancerJAMA Oncol201621465426562159
   PubMed Web of Science ®Google Scholar
• BalarAVCastellanoDO’DonnellPHFirst-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 studyLancet Oncol201718111483149228967485
   PubMed Web of Science ®Google Scholar
• ChalmersZRConnellyCFFabrizioDAnalysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burdenGenome Med2017913428420421
   PubMed Web of Science ®Google Scholar
• LlosaNJCruiseMTamAThe vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpointsCancer Discov201551435125358689
   PubMed Web of Science ®Google Scholar
• LeDTDurhamJNSmithKNMismatch repair deficiency predicts response of solid tumors to PD-1 blockadeScience2017357634940941328596308
   PubMed Web of Science ®Google Scholar
• GainorJFShawATSequistLVEGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective AnalysisClin Cancer Res201622184585459327225694
   PubMed Web of Science ®Google Scholar
• HarataniKHayashiHTanakaTTumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatmentAnn Oncol20172871532153928407039
   PubMed Web of Science ®Google Scholar
• DongZYZhongWZZhangXCPotential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung AdenocarcinomaClin Cancer Res201723123012302428039262
   PubMed Web of Science ®Google Scholar
• IbrahimEMAl-FoheidiMEAl-MansourMMKazkazGAThe prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysisBreast Cancer Res Treat2014148346747625361613
   PubMed Web of Science ®Google Scholar
• WolfGTChepehaDBBellileETumor infiltrating lymphocytes (TIL) and prognosis in oral cavity squamous carcinoma: a preliminary studyOral Oncol2015511909525283344
   PubMed Web of Science ®Google Scholar
• LiBSeversonEPignonJCComprehensive analyses of tumor immunity: implications for cancer immunotherapyGenome Biol201617117427549193
   PubMed Web of Science ®Google Scholar
• McGranahanNFurnessAJRosenthalRClonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockadeScience201635162801463146926940869
   PubMed Web of Science ®Google Scholar
• ZhengCZhengLYooJKLandscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell SequencingCell2017169713421356.e1628622514
   PubMed Web of Science ®Google Scholar
• ZhangXZhangWYuanXFuMQianHXuWNeutrophils in cancer development and progression: Roles, mechanisms, and implications (Review)Int J Oncol201649385786727573431
   PubMed Web of Science ®Google Scholar
• RakicABeaudryPMahoneyDJThe complex interplay between neutrophils and cancerCell Tissue Res2018371351752929427051
   PubMed Web of Science ®Google Scholar
• LairdBJFallonMHjermstadMJQuality of Life in Patients With Advanced Cancer: Differential Association With Performance Status and Systemic Inflammatory ResponseJ Clin Oncol201634232769277527354484
   PubMed Web of Science ®Google Scholar
• LiSXuXLiangDTianGSongSHeYPrognostic value of blood neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in patients with gastric cancerZhonghua Zhong Liu Za Zhi2014361291091525623765
   PubMedGoogle Scholar
• DiemSSchmidSKrapfMNeutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumabLung Cancer201711117618128838390
   PubMed Web of Science ®Google Scholar
• MartensAWistuba-HamprechtKGeukes FoppenMBaseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with IpilimumabClin Cancer Res201622122908291826787752
   PubMed Web of Science ®Google Scholar
• WeideBMartensAHasselJCBaseline Biomarkers for Outcome of Melanoma Patients Treated with PembrolizumabClin Cancer Res201622225487549627185375
   PubMed Web of Science ®Google Scholar
• MlecnikBBindeaGAngellHKIntegrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite InstabilityImmunity201644369871126982367
   PubMed Web of Science ®Google Scholar
• CaseySCTongLLiYMYC regulates the antitumor immune response through CD47 and PD-L1Science2016352628222723126966191
   PubMed Web of Science ®Google Scholar
• PengWChenJQLiuCLoss of PTEN Promotes Resistance to T Cell-Mediated ImmunotherapyCancer Discov20166220221626645196
   PubMed Web of Science ®Google Scholar
• WooSRFuertesMBCorralesLSTING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumorsImmunity201441583084225517615
   PubMed Web of Science ®Google Scholar
• FuJKanneDBLeongMSTING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockadeSci Transl Med20157283283ra252
   Web of Science ®Google Scholar
• MickePOstmanATumourstroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy?Lung Cancer200445Suppl 2S163S17515552797
   PubMedGoogle Scholar
• HeHQiLXiaoYHouYTumor Associated Fibroblasts Promote PD-L1 Expression in Lung Cancer CellsZhongguo Fei Ai Za Zhi201720529329728532535
   PubMedGoogle Scholar
• WeberJSGibneyGSullivanRJSequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trialLancet Oncol201617794395527269740
   PubMed Web of Science ®Google Scholar